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Abstract
The polyphenol compound resveratrol (RSV) has attracted attention due to
its reputed beneficial effects on insulin sensitivity. Our lab has previously
identified protective effects of RSV against the development of type 2 diabetes
in rats. These effects occurred in a manner similar to thiazolidinedione’s
(TZDs), a class of insulin sensitizing drugs. TZDs are commonly prescribed in
combination with metformin (MET) and thus we sought to examine the com-
bined effects of RSV and MET in treating insulin resistance. Male C57BL6
mice were fed a low- (LFD; 10% Kcal from fat) or high-fat diet (HFD; 60%
Kcal from fat) for 9 weeks to induce glucose and insulin intolerance. HFD
mice were then assigned to control (HFD), MET (231.28  12.24 mg/kg/day),
RSV (93.68  3.51 mg/kg/day), or combined (COM; MET 232.01  17.12
mg/kg/day and RSV 92.77  6.92 mg/kg/day) treatment groups. Changes in
glucose and insulin tolerance and tissue-specific insulin signaling were mea-
sured 4 weeks post-treatment. RSV or MET alone did not have beneficial
effects on glucose tolerance, although MET significantly improved insulin tol-
erance compared to HFD. Glucose and insulin tolerance were significantly
improved in COM compared to HFD and this was mirrored by enhanced
insulin-stimulated AKT phosphorylation in triceps muscle and inguinal subcu-
taneous adipose tissue in COM compared to HFD mice. Improvements with
COM treatment were not explained by differences in body weight, adiposity,
or markers of adipose tissue inflammation. In summary, this study provides
evidence of beneficial effects of combined RSV and MET therapy in treating
impairments in glucose homeostasis.
Introduction
The incidence of type 2 diabetes (T2D) is increasing at an
alarming rate and is one of the leading causes of non-
communicable disease deaths in the world (Mathers and
Loncar 2006). Insulin resistance is a precursor to the
development of T2D and therefore it is important to
identify treatment options for this condition. Two drugs
that are commonly used in the management of perturbed
glucose metabolism are metformin (MET) and thiazo-
lidinediones (TZDs). MET reduces hepatic liver glucose
output (Hundal et al. 2000) and enhances skeletal muscle
glucose uptake (Musi et al. 2002) and insulin signaling
(Luna et al. 2006), whereas TZDs increase insulin sensi-
tivity (Miyazaki et al. 2001, 2002), in part, due to reduc-
tions in adipose tissue inflammation (Xu et al. 2003) and
increases in the insulin sensitizing adipokine (Yamauchi
et al. 2002; Bruce et al. 2005) adiponectin (Nawrocki
et al. 2006). As MET and TZDs work through distinct
mechanisms, it is not surprising that dual therapy with
both drugs leads to greater improvements in glucose
homeostasis than either drug alone (Inzucchi et al. 1998;
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DeFronzo 1999; Stafford and Elasy 2007). Although effec-
tive in treating impaired glucose homeostasis, TZDs have
wide ranging adverse effects including increased risk of
congestive heart failure, myocardial infarction, and blad-
der cancer (Nissen and Wolski 2007; Turner et al. 2014).
Given this, it would be advantageous to identify treatment
approaches that might possess some of the same benefi-
cial effects as TZDs.
The polyphenol compound resveratrol (RSV) has
gained attention for its ability to protect against the
development of insulin resistance (Baur et al. 2006;
Lagouge et al. 2006; Beaudoin et al. 2013). For example,
we have recently shown that dietary RSV supplementation
prevents the development of T2D in Zucker Diabetic
Fatty rats and this was associated with increases in serum
adiponectin levels and adipose tissue mitochondrial con-
tent and respiration (Beaudoin et al. 2013), effects similar
to those of TZDs (Koh et al. 2007). In contrast to TZDs,
RSV possesses cardioprotective effects (Raj et al. 2014;
Sung and Dyck 2015) and has been reported to attenuate
growth rates of bladder cancer cells (Wu et al. 2014).
Given these points, it seems reasonable to assume that
RSV could be an attractive therapeutic option, either
alone, or in combination with MET, in treating insulin
resistance. Surprisingly, to the best of our knowledge, this
has never been explored. Within this context, the purpose
of the current investigation was to compare the effects of
RSV and MET, alone and in combination, in treating glu-
cose intolerance and insulin resistance in mice fed a high-
fat diet. We hypothesized that dual therapy would be
more effective than either compound alone.
Materials and Methods
Materials
Trans-resveratrol (CAT# 70675) and metformin (CAT#
13118) were purchased from Cayman Chemicals (Ann
Arbor, MI). Low-fat (LFD: 10% kcal from fat; CAT#
D12450B) and high-fat (HFD: 60% kcal from fat; CAT#
D12492) diets were purchased from Research Diets (New
Brunswick, NJ). Insulin was from Eli Lilly (Toronto, ON,
Canada) and glucose from BioShop (Burlington, ON,
Canada). Reagents, molecular weight marker and nitrocel-
lulose membranes for SDS-PAGE were purchased from
Bio-Rad. Antibodies against glyceraldehyde 3-phosphate
dehydrogenase (GAPDH; CAT# ab8245) and vinculin
(CAT# ab129002) were obtained from Abcam (Toronto,
ON, Canada). Total Akt (CAT# 4685), p-AKT threonine
308 (CAT# 9275) and p-AKT serine 473 (CAT# 9271)
antibodies were from Cell Signaling (Danvers, MA). An
antibody against the alpha subunit of glucose 6 phos-
phatase (G6Pase) (CAT# 25840) was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies
against phosphoenolpyruvate carboxykinase (PEPCK)
(CAT# 10004943) were a product of Cayman Chemicals
(Ann Arbor, MI). Western-Lightening Plus Enhanced
Chemiluminescence substrate (CAT# NEL105001EA) was
purchased from Perkin Elmer (Waltham, MA). Horserad-
ish peroxidase-conjugated donkey anti-rabbit and goat
anti-mouse IgG secondary antibodies were from Jackson
ImmunoResearch Laboratories (West Grove, PA). Super-
Script II Reverse Transcriptase, random primers and
dNTP were products from Invitrogen (Burlington, ON,
Canada). RNeasy mini kits and Quiazol were from
Qiagen (Toronto, ON, Canada). Taqman gene expression
assays for mouse GAPDH (CAT# 4352932), tumor
necrosis factor alpha (TNFa) (CAT #Mm0044358_m1),
F4/80 (Mm00802529_m1), and adiponectin (CAT# Mm
00456425_m1) were from Applied Biosystems. An ELISA
for mouse adiponectin (CAT # EZMADP-60K) was
obtained from Millipore (Etobicoke, ON).
Animals
Animal protocols were approved by the University of
Guelph Animal Care Committee and met Canadian
Council on Animal Care (CCAC) guidelines. Male
C57BL6 mice, 8 weeks of age (Charles River), were indi-
vidually housed with a 12:12 h light:dark cycle and ad libi-
tum access to water and experimental diets. Mice were
fed a LFD or HFD for 9 weeks, after which intraperi-
toneal glucose and insulin tolerance tests (IPGTT and
IPITT) were performed to confirm the presence of per-
turbed glucose metabolism. HFD mice were randomly
assigned to HFD-control, HFD-metformin (MET;
250 mg/kg/day), HFD-resveratrol (RSV; 100 mg/kg/day),
or a combination of both (COM; MET: 250 mg/kg/day
and RSV: 100 mg/kg/day). The doses of RSV and MET
used in this study are similar to those used in previous
rodent-based investigations (Fujita et al. 2002; Lagouge
et al. 2006; Hou et al. 2010; Beaudoin et al. 2013; Kris-
tensen et al. 2013). In a pilot experiment, we found that
250 mg/kg/day MET treatment lowered the glucose area
under the curve (AUC), during a glucose tolerance test
compared to untreated HFD mice (HFD 1941  344,
MET 1464  121) but not to levels seen in mice fed a
low-fat diet (1000  146). A lower dose of MET
(62.5 mg/kg/day) had negligible effects (1821  286) on
HFD-induced glucose tolerance.
Body weight (BW) and glucose homeostasis were simi-
lar at the onset of treatment. Treatments were added
directly to the food, in their powdered form, and manu-
ally mixed on a weekly basis, with amounts based on
average daily food intake and BW. The average dose of
MET and RSV consumed were than calculated at
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termination, based on average BW and daily food intake
per week as well as the dilution of treatment administered
in food. IPGTT and IPITT were repeated following
4 weeks of treatment. Animal and food weights were
monitored 1 and 3 days/week, respectively, throughout
the duration of the study.
Glucose and insulin tolerance testing
Intraperitoneal glucose and insulin tolerance tests (IPGTT
and IPITT) were performed as measures of glucose home-
ostasis. For the IPGTT, mice were fasted for 6 h prior to
an IP injection of glucose (2 g/kg BW). For the IPITT
measures, food was removed immediately prior to an IP
injection of insulin (0.5 U/kg). Blood glucose concentra-
tions were determined via tail vein sampling using a
hand-held glucometer (Freestyle Lite, Abbott). IPGTT
and IPITT measures were performed 48 hours apart as
previously described (Beaudoin et al. 2013), with mice
given ad libitum access to their respective diets between
tests. Relative changes in IPGTT and IPITT measures
compared to the HFD were calculated and independent
MET and RSV changes were summed to predict the
effects of combined therapy.
Tissue collection
After 4 weeks of treatment, and 72 h following the last
tolerance test, mice were anesthetized with sodium pento-
barbital (5 mg/100 g, IP injection) and inguinal subcuta-
neous (scAT) and epididymal (eWAT) adipose tissue
depots and triceps from the left side of mice were excised,
weighed, and flash frozen or fixed in formalin. Mice were
injected with insulin (1.25 U/kg) and 10 min postinjec-
tion, contralateral tissues and the liver were excised,
weighed, and flash frozen. Intrathoracic blood was col-
lected at this time. Tissues were stored at 80°C until
further analysis.
Histology
Approximately 100 mg of eWAT and scAT were fixed in
10% neutral-buffered formalin (VWR, Mississauga, ON,
Canada), dehydrated in 70% ethanol (Fisher Scientific),
and embedded in paraffin. Five micrometer sections were
mounted on 1.2 mm Superfrost slides, stained with Har-
ris hematoxylin and eosin stock (H&E; Fisher Scientific)
and imaged (Olympus FSX 100 light microscope, Olym-
pus, Tokyo, Japan) as previously described (MacPherson
et al. 2015). Cells were sampled in each image to deter-
mine cross-sectional area (>200 cells/mouse) (ImageJ
software, National Institute of Mental Health, Bethesda,
MD). The presence of crown-like structures was
determined as we have described in detail previously
(MacPherson et al. 2016).
Western blotting
Samples were homogenized in 3 (scAT and eWAT), 20
(triceps), or 30 (liver) volumes of NP40 Cell Lysis Buffer
(Life Technologies; CAT# FNN0021) supplemented with
phenylmethylsulfonyl fluoride and protease inhibitor
cocktail (Sigma; CAT# 78830, CAT# P2714) using a Fas-
tPrep-24 Tissue Homogenizer (MP Biomedicals) as previ-
ously described (MacPherson et al. 2015). Homogenized
samples were centrifuged at 4°C for 10 min at 1500 9 g
and the supernatant collected from liver and skeletal mus-
cle, while the infranatant was collected from adipose tis-
sue. A bicinchoninic acid assay was performed to
determine protein content of the homogenate (Smith
et al. 1985). Equal amounts of protein were then elec-
trophoretically separated on 10% SDS-PAGE gels and
transferred to nitrocellulose membranes. Membranes were
blocked for 1 h at room temperature in 5% non-fat dry
milk-TBST (tris-buffered saline/0.1% tween 20). Mem-
branes were then incubated in primary antibody diluted
1:1000 in 5% BSA (Bovine Serum Albumin)-TBST over-
night with gentle agitation at 4°C. Following a 1-hour
incubation at room temperature with appropriate sec-
ondary antibodies, in 1% non-fat dry milk-TBST, mem-
branes were washed and proteins visualized by Western
Lightning Plus-ECL using a Flourochem HD2 imager
(Cell Biosciences) and bands quantified using Alpha Inno-
tech software (Santa Clara, CA). A housekeeping protein
(GAPDH) was measured in each gel to ensure equal load-
ing.
RT-PCR
Changes in mRNA expression were determined using
real-time qPCR as described in detail previously by our
laboratory (MacPherson et al. 2015). RNA was isolated
from scAT and eWAT using a Qiagen RNeasy kit accord-
ing to the manufacturer’s instructions. Complementary
DNA (cDNA) was synthesized from 1lg of total RNA
using SuperScript II Reverse Transcriptase, random pri-
mers, and dNTP. Real-time PCR was carried out using
the CFX Connect Real-Time PCR Detection System (Bio-
Rad). Each well contained 1 lL of cDNA template, 8 lL
of RNase free water, 1 lL gene expression assay, and
10 lL of Taqman Fast Universal PCR Master Mix. Rela-
tive differences between groups were determined using
the 2ΔΔCT method (Livak and Schmittgen 2001). The
amplification efficiencies of the gene of interest and the
housekeeping gene were equivalent and the expression of
GAPDH did not change between groups.
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Adiponectin ELISA
Circulating concentrations of adiponectin were measured
by ELISA as described previously (Beaudoin et al. 2013).
Statistical analysis
Differences between LFD and HFD before treatment were
examined by one-tailed t-test. A one-tailed t-test was cho-
sen a priori based on the prevalence of literature demon-
strating impaired glucose and insulin tolerance following
long-term HFD. For examination of blood glucose differ-
ences at individual time-points during glucose and insulin
tolerance testing in LFD and HFD mice, a repeated mea-
sures ANOVA was performed with a Sidak’s multiple
comparisons test. A one-way ANOVA with Tukey’s post
hoc analysis was used to determine differences between
treatment groups. When data were not normally dis-
tributed, as measured with Shapiro–Wilk normality test-
ing, data were log transformed to achieve normal
distribution. To examine differences in AKT phosphoryla-
tion between and within groups (basal vs. insulin-stimu-
lated) and differences in blood glucose at individual time-
points during IPGTT and IPITT between treatment
groups, a two-way repeated measures ANOVA with
Tukey’s post hoc analysis was used. A relationship was
considered significant when P < 0.05.
Results
High-fat diet induces glucose and insulin
intolerance
Animals fed the HFD weighed significantly more than LFD
mice following 9 weeks of feeding (Fig. 1A) and displayed
impairments in glucose homeostasis as evidenced by higher
glucose AUCs during the IPGTT (Fig. 1B and C) and
IPITT (Fig. 1D and E). Specifically, HFD mice displayed
significantly increased blood glucose concentrations
between 15 and 90 min during the IPGTT and between 15
and 60 min during the IPITT, which is indicative of
impaired whole-body glucose homeostasis (Fig. 1B and D).
Treatment interventions (MET, RSV, and COM) were initi-
ated at this time. As we were interested in examining the
effects of RSV and/or MET in treating impaired glucose
homeostasis, only HFD mice were studied. Body weights
and glucose and insulin tolerance were not different
between groups at the onset of treatment (data not shown).
Food intake, body weight, and adiposity
Four weeks of MET (231.28  12.24 mg/kg/day), RSV
(93.68  3.51 mg/kg/day), or COM (MET 232.01  17.12
mg/kg/day; RSV 92.77  6.92 mg/kg/day) treatment had
no effect on BW or food intake compared to HFD (Fig. 2A
and B). However, RSV exhibited significantly reduced
eWAT weight compared to MET and COM (Fig. 2C), as
well as significantly increased liver weight compared to
HFD (Fig. 2D). No differences were observed in adipocyte
size in eWAT or scAT between groups (Fig. 2E–G).
Whole-body glucose homeostasis and
insulin action
To assess the effects of MET and RSV on glucose home-
ostasis, we first performed IPGTTs following 4 weeks of
treatment with MET, RSV, and COM. As shown in Fig-
ure 3A and B, both RSV and MET treatment alone did
not improve glucose intolerance in mice fed a HFD,
although MET displayed significantly lower blood glucose
than HFD at 90 min. However, when given in combina-
tion, glucose tolerance was significantly improved, as
shown by a lower IPGTT AUC in COM compared to
HFD. COM mice had significantly lower blood glucose
compared to HFD at 45, 60, and 90 min during the
IPGTT. We then calculated differences in the glucose
AUCs relative to the untreated HFD mice (i.e., HFD
mice = 100). Interestingly, the predicted improvement in
glucose tolerance with both compounds in combination
was essentially identical to the observed COM effects
(Fig. 3C).
We further evaluated the individual and combined
effects of MET and RSV on glucose homeostasis using
an IPITT. RSV alone did not improve insulin tolerance
compared to HFD (Fig. 3D and E). However, MET and
COM significantly lowered the IPITT AUC compared to
HFD, indicative of improved insulin tolerance in these
groups (Fig. 3E). The COM group had significantly
lower blood glucose compared to HFD at 15, 30, 45, 60,
and 90 min, while MET was only significantly different
at 15, 45, and 60 min during the IPITT. The predicted
additive effects of combined treatment were again simi-
lar to the observed improvements with COM treatment
(Fig. 3F).
Tissue specific insulin action
In order to evaluate tissue-specific effects of our treat-
ments on insulin action, AKT phosphorylation at S473
and T308 activation sites were examined in triceps and
adipose tissue prior to and following an IP bolus injection
of insulin. Liver was only examined post-insulin, as pre-
insulin samples could not be obtained.
There were no differences in AKT phosphorylation
between groups in the liver (Fig. 4A–C). Insulin signifi-
cantly increased triceps S473 and T308 AKT
2016 | Vol. 4 | Iss. 15 | e12877
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phosphorylation in all groups compared to basal
(Fig. 4D–F). COM treatment exhibited greater insulin-sti-
mulated AKT S473 phosphorylation in triceps compared
to HFD or RSV alone. Insulin-induced S473 phosphoryla-
tion was greater in triceps muscles from MET compared
to RSV-treated mice (Fig. 4E). No differences were
observed in insulin-induced AKT T308 phosphorylation
in triceps between groups (Fig. 4F).
Insulin increased S473 and T308 AKT phosphorylation
in eWAT and scAT in all groups compared to basal, with
the exception of RSV which did not exhibit increased
AKT T308 phosphorylation following insulin-stimulation
in eWAT (Fig. 4G–I). No differences in eWAT AKT
phosphorylation were observed between groups (Fig. 4G–
I). COM treatment significantly increased insulin-stimu-
lated S473 and T308 AKT phosphorylation in scAT com-
pared to all other groups (Fig. 4J–L).
Gluconeogenic enzyme protein content
To determine if changes in gluconeogenic enzymes in the
liver could explain the improvements in glucose home-
ostasis, we measured changes in PEPCK and G6Pase. The
protein content of PEPCK and G6Pase was not different
in livers from HFD, MET, RSV, or COM treated mice
(Figure S1).
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Adiponectin and inflammatory gene
expression in adipose tissue
In order to examine potential mechanisms responsible for
the whole-body effects of COM treatment, we examined
adiponectin expression in adipose tissue and plasma, as
well as inflammatory gene expression in adipose tissue.
No differences between groups were observed in adipo-
nectin expression in eWAT (Fig. 5A) or scAT (Fig. 5B).
However, COM exhibited significantly reduced plasma
adiponectin compared to HFD (Fig. 5C).
Adipose tissue inflammation is thought to play a role
in the development of insulin resistance (Xu et al. 2003;
Lee et al. 2011). As such, we were interested in examining
if RSV and/or MET treatment altered markers of adipose
tissue inflammation. As shown in Figure 6, no differences
were observed in the mRNA expression of TNF-a or
interleukin 6 (IL6) in eWAT and scWAT. Moreover, the
mRNA expression of F4/80, a marker of macrophage con-
tent (Leenen et al. 1994) was not affected by treatment
with RSV and MET either alone or in combination in
both fat depots. As a further measure of inflammation,
we assessed the number of crown-like structures (CLS) in
H&E-stained scAT sections. This fat depot was analyzed
as the most robust changes in insulin-stimulated AKT
phosphorylation occurred in this fat pad. There were no
differences in the percentage of adipocytes that were sur-
rounded by CLS between groups (HFD 1.83  0.51, MET
0.93  0.27, RSV 1.07  0.30, COM 0.99  0.31, data
are means  SEM for 5 mice/group).
Discussion
To the best of our knowledge, this is the first study to
compare the individual and combined effects of RSV and
MET in treating perturbations in glucose metabolism. In
this regard, MET and RSV treatment alone did not signif-
icantly improve glucose tolerance, though it should be
noted that the glucose AUC was reduced ~20% and 10%
in MET- and RSV-treated mice, respectively. However,
when given in combination, there was a significant
improvement in glucose tolerance. In fact, the observed
improvements in glucose tolerance with COM treatment
were nearly identical to the sum of RSV and MET
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improvements administered independently and would
suggest an additive effect between these two compounds.
Although the dose of RSV used in this study is similar to
what has been used in previous rodent-based investiga-
tions (Lagouge et al. 2006), it is far greater than the max-
imal dose recommended for long-term clinical use in
humans (EFSA Panel on Dietetic Products NaA, 2016).
Given the likely limited translatability to humans,
the results of the current investigation should be viewed
cautiously.
The findings of the current investigation are similar to
those of a previous study that found improved whole-
body insulin sensitivity with a combination of MET, RSV,
and hydroxymethylbutyrate (HMB) treatment (Bruck-
bauer and Zemel 2013). However, this study used a
genetic model of diabetes, male db/db mice (C57BLK6/J-
leprdb/leprdb), and the dose of RSV that was used
(12.5 mg/kg diet) was much lower than that in the cur-
rent investigation. Similarly, HMB was given at a compar-
atively larger dose than both RSV and MET and therefore
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the results of this particular study are most likely a result
of the combined effects of MET and HMB, not RSV.
While MET has consistently been shown to improve
glucose homeostasis in conditions of insulin resistance
(Stafford and Elasy 2007), the effects of RSV are less clear.
For instance, while RSV treatment prevents the develop-
ment of diet-induced insulin resistance in rodents (Baur
et al. 2006; Lagouge et al. 2006; Beaudoin et al. 2013),
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RSV supplementation, especially in humans, has marginal
effects on improving glucose homeostasis in conditions of
pre-existing insulin resistance and obesity (Timmers et al.
2011; Yoshino et al. 2012; Faghihzadeh et al. 2015). At
least at the doses utilized in this study, MET would
appear to be more effective than RSV in improving glu-
cose homeostasis. In support of this contention, insulin
tolerance was improved in MET but not RSV-treated
mice. Moreover, improvements in glucose tolerance, as
measured through reductions in glucose AUC, were ~2
fold greater in MET compared to RSV-treated mice.
Lastly, insulin-stimulated AKT phosphorylation in eWAT
and triceps muscles were reduced in RSV, but not MET-
treated mice when compared to control HFD mice. These
findings, taken in context with previous work (Baur et al.
2006; Lagouge et al. 2006; Beaudoin et al. 2013), would
suggest that RSV is more effective in preventing the
development of insulin resistance than treating it.
The improvements in whole-body glucose homeostasis
following COM treatment were mirrored by increases in
insulin-stimulated AKT phosphorylation in scAT and to a
lesser extent triceps muscle. Although MET is not thought
to increase adipose tissue insulin action (Ciaraldi et al.
2002), long-term (13 week) RSV treatment has been
reported to increase insulin signaling in this tissue (Svens-
son et al. 2015). Conversely, treating 3T3-L1 adipocytes
with a high dose of RSV (50 lmol/L) has been shown to
induce insulin resistance (Wang et al. 2011). In this
study, we found that the insulin-induced phosphorylation
of AKT on threonine 308 was markedly impaired in
eWAT from RSV-treated mice. As both MET and RSV
did not improve, and in some cases reduced, insulin sig-
naling in adipose tissue, enhanced insulin-stimulated AKT
phosphorylation with COM treatment likely speaks to a
synergistic effect of these two compounds in improving
scAT insulin signaling.
The association between increases in scAT and triceps
insulin signaling and improvements in glucose tolerance
in COM-treated mice suggests a role for enhanced insulin
signaling in these tissues being involved in improvements
in whole-body glucose homeostasis. Consistent with the
potential importance of scAT in mediating whole-body
improvements in glucose homeostasis, a recent study has
reported similar associations between key proteins
involved in insulin signaling (AKT, GLUT4) in subcuta-
neous adipose tissue and indices of insulin sensitivity in
obese subjects following diet-induced weight loss (Fritzen
et al. 2015).
While we have demonstrated a clear enhancement of
insulin signaling in scAT, this does not appear to be
explained by alterations in markers of inflammation, or
through increases in the expression, or circulating levels,
of adiponectin. Moreover, the effects of RSV and MET in
combination are not secondary to differences in body
weight or adiposity (i.e., fat cell size and adipose tissue
weight). Future work aimed at identifying the cellular
events leading to enhanced insulin signaling in adipose
tissue with dual RSV and MET therapy is needed and
could help in identifying new targets to improve glucose
homeostasis.
In summary, this study has been the first to compare
the individual and combined effects of MET and RSV in
the treatment of insulin resistance. MET appears to be
more effective in treating insulin resistance than RSV, at
least at the concentrations utilized. Moreover, we have
provided evidence of potential beneficial effects of com-
bined RSV and MET treatment on indices of whole-body
glucose homeostasis that might be explained, at least in
part, through increases in insulin signaling in adipose tis-
sue and muscle.
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